Press Releases Veracyte, Inc.

Equities

VCYT

US92337F1075

Real-time Estimate Cboe BZX Other stock markets 01:24:32 2024-06-03 pm EDT			5-day change	1st Jan Change
20.87 ^USD	+0.58%		-2.70%	-24.14%

May. 07	Earnings Flash (VCYT) VERACYTE Posts Q1 Revenue $96.8M, vs. Street Est of $93.4M	MT
May. 07	Transcript : Veracyte, Inc., Q1 2024 Earnings Call, May 07, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer	May. 22	BU
Veracyte to Participate in Upcoming Investor Conferences	May. 15	BU
Veracyte: Q1 Earnings Snapshot	May. 07	AQ
Veracyte Announces First Quarter 2024 Financial Results	May. 07	BU
14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding	May. 06	BU
New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression among Patients Undergoing Active Surveillance	Apr. 23	AQ
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024	Apr. 22	BU
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance	Apr. 22	BU
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024	Apr. 16	BU
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines	Feb. 27	BU
Veracyte: Q4 Earnings Snapshot	Feb. 22	AQ
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results	Feb. 22	BU
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference	Feb. 21	BU
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024	Feb. 08	BU
Veracyte Completes Acquisition of C2i Genomics	Feb. 06	BU
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform	Jan. 08	BU
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 12	BU
Real-World Data Presented at SUO 2023 Show that Veracyte's Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress	Dec. 04	AQ
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress	Dec. 01	BU
Clinical Validation Data Published in CHEST Demonstrate that Veracyte's Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules	Nov. 30	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Veracyte, Inc.

Equities

VCYT

US92337F1075

Press Releases

Filters